Phase I Evaluation of Chlorozotocin (NSC-178248): Weekly Schedule
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Abstract
A phase I trial of chlorozotocin was completed for a weekly times four dose schedule repeated every 8 weeks. Thrombocytopenia was the acute dose limiting toxicity. Nausea and vomiting were moderate to severe and dose related. Two cases of possible drug related irreversible nephrotoxicity were seen. Transient elevations of serum creatinine and mild proteinuria were noted. Also, transient elevations in SGOT were observed. One patient with a carcinoid tumor had a 60% reduction in his 5HIAA level after one course of therapy. The recommended dose for phase II clinical studies of chlorozotocin is 40 mg/m2 IV weekly for four weeks, repeated every 8 weeks.
References
1.
Hoth D, Woolley P, Green D, Macdonald J, Schein P
. Phase I studies on chlorozotocin. Clin Pharmacol Ther. 1978; 23(6):712-22.
DOI: 10.1002/cpt1978236712.
View
2.
Byrne P, Tew K, Jemionek J, MacVittie T, Erickson L, Schein P
. Cellular and molecular mechanisms of the bone marrow sparing effects of the glucose chloroethylnitrosourea chlorozotocin. Blood. 1984; 63(4):759-67.
View
3.
Anderson T, McMenamin M, Schein P
. Chlorozotocin, 2-(3-(2-chloroethyl)-3-nitrosoureido)-D-glucopyranose, an antitumor agent with modified bone marrow toxicity. Cancer Res. 1975; 35(3):761-5.
View
4.
Gralla R, Tan C, Young C
. Phase I trial of chlorozotocin. Cancer Treat Rep. 1979; 63(1):17-20.
View
5.
Schein P, Panasci L, Woolley P, Anderson T
. Pharmacology of chlorozotocin Nsc-178248), a new nitrosourea antitumor agent. Cancer Treat Rep. 1976; 60(6):801-5.
View